Company Overview and News
Dover Corporation’s (DOV - Free Report) Fluids segment unit, Maag, recently clinched a contract from Hainan Huasheng New Material Technology Co. Ltd. Per the deal, Maag will supply pumps, pelletizing systems and screen changers to Hainan Huasheng’s new polycarbonate-production facility in China. After completion in 2020, the facility will be able to produce up to 260 kilotons per annum of polycarbonate.
DOV.WI B CFX DOV UTX FLS EOG
CAIRO (Sept 15): Egypt has signed a deep-water oil and gas exploration deal with Royal Dutch Shell and Malaysia's Petronas worth around US$1 billion for 8 wells in the country's West Nile Delta, the petroleum ministry said on Saturday.
RDS.B DOV.WI RDS.A RYDBF DOV RDSB RDSA RYDAF
Shares of Dover Corporation (DOV - Free Report) reached a new high after it announced a rightsizing plan to improve the company’s operating margin performance. The move will also enhance its operations, thereby facilitating sustainable growth and investments. Dover’s shares crafted a 52-week high of $88.60 during intra-day trading, finally closing lower at $86.22, on Sep 11. During the June-end quarter, Dover’s selling, general and administrative (SG&A) costs flared up 1.
DOV.WI B CFX DOV FLS
Dover Corporation (DOV - Free Report) has been witnessing encouraging improvement over the past few quarters, majorly driven by strong bookings, cost-reduction initiatives and restructuring programs. The company will benefit from the spin-off of Apergy. However, challenges in the Fluids segment and foreign-exchange volatility remain headwinds. This Zacks Rank #3 (Hold) company has an estimated long-term earnings growth rate of 12%.
DOV.WI GWW SCVL ATKR IRBT DOV PAYC
One popular form of dividend investing involves a group of stocks called dividend aristocrats. Standards of what makes up a dividend aristocrat vary. However, most analysts define it by three criteria. One, they must belong to the S&P 500 index. Two, they meet specific size and liquidity metrics. Three, and most importantly, they must have increased their dividend for 25 or more consecutive years.
IBM PG AMZN DOV.WI T JNJ TSLA CSCO DOV
2018-08-12 seekingalpha - 7
Dan Loeb's 13F portfolio value increased from $13.32B to $14.35B this quarter. The number of positions decreased from 40 to 38.
ATHTF STZ.B TWX CRM DOW DOV MELI PBF TPRE WP KDMN STZ UTX BKI TWC PVH DVMT FPAC.U GOOGL MSFT APY MHK TPNTF GRBK FB DOV.WI LEN NXPI PYPL NFLX BAX GOOG LEN.B MPC PAGS ADBE SPGI EGN MON ICE SHY CWH EA WYNN ANTM DWDP BID BLK V DHR ANTX
THE WOODLANDS, Texas, July 25, 2018 (GLOBE NEWSWIRE) -- Apergy Corporation (“Apergy”) (NYSE:APY) today reported net income in the second quarter of 2018 of $22.2 million, compared to net income of $18.8 million in the second quarter of 2017. Diluted earnings per share in the second quarter of 2018 was $0.29 and include total after-tax charges of $7.2 million, or $0.09 per diluted share, related to spin-off and other restructuring activities.
APY.WI DOV.WI DOV APY
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process.
DOV.WI DOV RPM
Dover Corporation (DOV - Free Report) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. The stock picked up sharply from the near-flat trend of $72.45 to $74.91 in the past one month time frame.
CFIN DOV.WI KDP CIWV DOV RF GTLS
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET